Probity Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.37M | Buy |
48,878
+4,078
| +9% | +$109K | 0.22% | 82 |
|
|
2025
Q4 | $1.12M | Sell |
44,800
-3,960
| -8% | -$99.9K | 0.18% | 89 |
|
|
2025
Q3 | $1.24M | Sell |
48,760
-939
| -2% | -$23.2K | 0.2% | 83 |
|
|
2025
Q2 | $1.2M | Buy |
49,699
+8,268
| +20% | +$193K | 0.21% | 81 |
|
|
2025
Q1 | $1.05M | Buy |
41,431
+1,423
| +4% | +$37.2K | 0.2% | 82 |
|
|
2024
Q4 | $1.06M | Sell |
40,008
-772
| -2% | -$20.9K | 0.2% | 85 |
|
|
2024
Q3 | $1.18M | Buy |
40,780
+3,175
| +8% | +$92.6K | 0.23% | 83 |
|
|
2024
Q2 | $1.05M | Buy |
37,605
+2,851
| +8% | +$78.5K | 0.22% | 84 |
|
|
2024
Q1 | $964K | Sell |
34,754
-33
| -0.1% | -$916 | 0.2% | 97 |
|
|
2023
Q4 | $1M | Sell |
34,787
-1,189
| -3% | -$35.9K | 0.22% | 89 |
|
|
2023
Q3 | $1.19M | Buy |
35,976
+2,210
| +7% | +$78.2K | 0.28% | 55 |
|
|
2023
Q2 | $1.24M | Buy |
+33,766
| New | +$1.31M | 0.27% | 57 |
|
|
2022
Q4 | $1.77M | Sell |
34,482
-650
| -2% | -$31.2K | 0.4% | 44 |
|
|
2022
Q3 | $1.54M | Sell |
35,132
-2,301
| -6% | -$112K | 0.38% | 45 |
|
|
2022
Q2 | $1.96M | Sell |
37,433
-748
| -2% | -$38.1K | 0.45% | 38 |
|
|
2022
Q1 | $1.98M | Sell |
38,181
-3,219
| -8% | -$167K | 0.41% | 42 |
|
|
2021
Q4 | $2.44M | Sell |
41,400
-550
| -1% | -$27.3K | 0.48% | 38 |
|
|
2021
Q3 | $1.8M | Buy |
41,950
+844
| +2% | +$37.4K | 0.37% | 52 |
|
|
2021
Q2 | $1.61M | Sell |
41,106
-243
| -0.6% | -$9.45K | 0.34% | 55 |
|
|
2021
Q1 | $1.5M | Buy |
+41,349
| New | +$1.47M | 0.33% | 56 |
|
|
2020
Q3 | $1.45M | Sell |
41,592
-515
| -1% | -$18.1K | 0.41% | 50 |
|
|
2020
Q2 | $1.31M | Buy |
42,107
+959
| +2% | +$32.6K | 0.4% | 50 |
|
|
2020
Q1 | $1.27M | Sell |
41,148
-1,094
| -3% | -$37.3K | 0.47% | 47 |
|
|
2019
Q4 | $1.57M | Sell |
42,242
-516
| -1% | -$18.4K | 0.47% | 47 |
|
|
2019
Q3 | $1.46M | Buy |
42,758
+1,065
| +3% | +$38.7K | 0.47% | 50 |
|
|
2019
Q2 | $1.71M | Sell |
41,693
-1,021
| -2% | -$40.5K | 0.57% | 39 |
|
|
2019
Q1 | $1.72M | Buy |
42,714
+1,869
| +5% | +$74.8K | 0.59% | 42 |
|
|
2018
Q4 | $1.69M | Sell |
40,845
-1,289
| -3% | -$53.5K | 0.63% | 40 |
|
|
2018
Q3 | $1.76M | Sell |
42,134
-821
| -2% | -$31.6K | 0.57% | 43 |
|
|
2018
Q2 | $1.48M | Sell |
42,955
-71
| -0.2% | -$2.43K | 0.52% | 46 |
|
|
2018
Q1 | $1.45M | Buy |
43,026
+638
| +2% | +$21.9K | 0.5% | 46 |
|
|
2017
Q4 | $1.46M | Buy |
42,388
+886
| +2% | +$30.2K | 0.51% | 41 |
|
|
2017
Q3 | $1.41M | Buy |
41,502
+583
| +1% | +$18.7K | 0.52% | 39 |
|
|
2017
Q2 | $1.3M | Buy |
40,919
+1,788
| +5% | +$56.4K | 0.49% | 41 |
|
|
2017
Q1 | $1.27M | Buy |
39,131
+2,592
| +7% | +$81.7K | 0.49% | 42 |
|
|
2016
Q4 | $1.13M | Buy |
36,539
+2,985
| +9% | +$91.1K | 0.47% | 46 |
|
|
2016
Q3 | $1.08M | Sell |
33,554
-36
| -0.1% | -$1.2K | 0.47% | 47 |
|
|
2016
Q2 | $1.12M | Buy |
+33,590
| New | +$1.07M | 0.5% | 44 |
|
Other funds holding PFE
VCM
VPM
Probity Advisors's PFE Position: Q1 2026 in Review
Probity Advisors increased its Pfizer (PFE) stake by 9.1% in Q1 2026, buying an estimated $109K and bringing the position to 48,878 shares worth $1.37M. The position accounts for 0.22% of the portfolio, ranked #82.
Probity Advisors first reported a position in PFE in Q2 2016 and has held it in 38 quarters since. The position peaked at $2.44M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Probity Advisors held 48,878 shares of Pfizer worth $1.37M as of Q1 2026.
- Probity Advisors bought 4,078 Pfizer shares in Q1 2026, an estimated $109K.
- Pfizer made up 0.22% of Probity Advisors's portfolio in Q1 2026, its #82 holding.
- Probity Advisors first reported a position in Pfizer in Q2 2016 and has held it in 38 quarters since.
- Probity Advisors's Pfizer position peaked at $2.44M in Q4 2021.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Probity Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.